WEBER EFFECT: AN EXTENDED ANALYSIS FOR TEN YEARS OF REPORTING TRENDS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

被引：6
|
作者：
Beulah, E. [1 ]
Reddy, N. [2 ]
Subeesh, V [3 ]
Maheswari, E. [3 ]
Pudi, C. [3 ]
机构：
[1] MS Ramaiah Univ Appl Sci, Bengalore, India
[2] Ramaiah Univ Appl Sci, Bangalore, Karnataka, India
[3] MS Ramaiah Univ Appl Sci, Bangalore, Karnataka, India
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2200
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM79
引用
收藏
页码：S369 / S369
页数：1
相关论文
共 50 条
  • [1] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    [J]. HELIYON, 2024, 10 (17)
  • [2] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [3] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    [J]. BMC Pharmacology and Toxicology, 24
  • [5] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [6] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [7] Carfiilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)
    Buck, Benjamin
    Kellett, Eric
    Addison, Daniel
    Vallakati, Ajay
    [J]. JOURNAL OF THE SAUDI HEART ASSOCIATION, 2022, 34 (03) : 134 - 141
  • [8] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [9] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    [J]. HELIYON, 2024, 10 (14)
12345